Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioartificial liver support devices: historical perspectives.

Fiona G Court1, Simon A Wemyss-Holden, Ashley R Dennison

  • 1University of Adelaide, Department of Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.

ANZ Journal of Surgery
|September 6, 2003
PubMed
Summary

Fulminant hepatic failure (FHF) has high mortality, but bioartificial liver support offers hope. These devices aim to replace liver functions, potentially improving survival for patients awaiting transplants or ineligible for them.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-technical Errors, a Hidden Contributor to Patient Mortality in Emergency General Surgery: A National Retrospective Cohort Study.

Annals of surgery·2026
Same author

Extended validation of the mesh integration (MINT) index: a 1-year porcine study.

Surgical endoscopy·2026
Same author

Surgical Conflicts of Interest: Are They a Problem?

ANZ journal of surgery·2026
Same author

Aortocoronary Versus Composite Grafting Strategies in Coronary Artery Bypass Surgery: a Network Meta-analysis.

The Canadian journal of cardiology·2026
Same author

Potentially Preventable Mortality After Elective Colorectal Cancer Surgery: Insights From a National Surgical Mortality Audit.

ANZ journal of surgery·2026
Same author

The mannose receptor on sinusoidal lining cells mediates two-step bacterial clearance in the human spleen.

Nature communications·2026

Area of Science:

  • Hepatology and Bioengineering
  • Critical Care Medicine

Background:

  • Fulminant hepatic failure (FHF) presents a significant global health challenge with survival rates around 20% despite advanced critical care.
  • Liver transplantation, the primary curative treatment, is limited by organ availability and patient eligibility, leading to high mortality.
  • Many cases of FHF are potentially reversible if temporary hepatic support can be provided, allowing for natural liver regeneration.

Observation:

  • Bioartificial liver support (BAL) devices are being developed to temporarily replace the synthetic, metabolic, and detoxification functions of a failing liver.
  • Recent advancements in bioengineering have focused on refining membrane technology and hepatocyte integration within BAL systems to enhance their efficacy.
  • Clinical trials are evaluating the performance of these BAL devices, exploring their potential to bridge patients to recovery or transplantation.

Related Experiment Videos

Findings:

  • BAL devices aim to provide crucial metabolic and detoxification functions, supporting liver regeneration in FHF patients.
  • Improvements in membrane technology and cell-support systems are key to enhancing the functional capacity of bioartificial livers.
  • The review covers the historical development, challenges, and current status of various liver support systems under evaluation.

Implications:

  • BAL devices represent a promising alternative or adjunct to liver transplantation for FHF patients, potentially increasing survival rates.
  • Successful implementation of BAL could reduce the reliance on organ transplantation and mitigate associated risks like immunosuppression.
  • Further development and clinical validation of BAL systems are crucial for their integration into standard FHF treatment protocols.